Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. covers the month of January 2023. The report addresses a corporate governance event regarding the company's Extraordinary General Meeting of Shareholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural announcement and does not contain financial statements or performance data.
Material Changes
There are no material financial changes reported. The primary event is the adjournment of the Extraordinary General Meeting of Shareholders originally scheduled for January 24, 2023, due to a lack of the required legal quorum.
Guidance, Outlook, and Management Commentary
Management has announced that the Extraordinary General Meeting will reconvene on January 25, 2023, at 3:00 p.m. Israel time at the Company's office. No financial guidance, risk factors, or unusual items are disclosed in this specific filing.
Key Facts for Investor Verification
- The Extraordinary General Meeting scheduled for January 24, 2023, was adjourned due to insufficient quorum.
- The meeting is rescheduled for January 25, 2023, at 3:00 p.m. Israel time.
- The meeting location is the Company's office in Tel Aviv, Israel.
- This filing contains no financial performance data or updated business outlook.